Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
Primary respiratory and intensive care center, University Hospital Dubrava, Zagreb, Croatia.
Wien Klin Wochenschr. 2022 May;134(9-10):377-384. doi: 10.1007/s00508-021-01999-5. Epub 2022 Jan 17.
C‑reactive protein (CRP) and albumin are inflammation sensitive parameters that are regulated by interleukin‑6 inflammatory pathways. The CRP to albumin ratio (CAR) integrates these two into a potent clinical parameter whose clinical and prognostic association in the context of coronavirus disease 2019 (COVID-19) have not been well defined. We aimed to investigate the clinical and prognostic significance of CAR in the context of COVID-19 infection.We retrospectively analyzed 2309 consecutive COVID-19 patients hospitalized at a tertiary level hospital in the period from March 2020 to March 2021 who had baseline data for a CAR assessment. Findings were validated in an independent cohort of 1155 patients hospitalized from March 2021 to June 2021.The majority of patients (85.8%) had severe or critical COVID-19 on admission. Median CRP, albumin and CAR levels were 91 mg/L, 32 g/L and 2.92, respectively. Higher CAR was associated with a tendency for respiratory deterioration during hospitalization, increased requirement of high-flow oxygen treatment and mechanical ventilation, higher occurrence of bacteriemia, higher occurrence of deep venous thrombosis, lower occurrence of myocardial infarction, higher 30-day mortality and higher postdischarge mortality rates. We defined and validated four CAR prognostic categories (< 1.0, 1.0-2.9, 3.0-5.9 and ≥ 6.0) with distinct 30-day survival. In the series of multivariate Cox regression models we could demonstrate robust prognostic properties of CAR that was associated with inferior 30-day survival independently of COVID-19 severity, age and comorbidities and additionally independently of COVID-19 severity, CURB-65 and VACO index in both development and validation cohorts.The CAR seems to have a good potential to improve prognostication of hospitalized COVID-19 patients.
C-反应蛋白(CRP)和白蛋白是受白细胞介素-6 炎症途径调节的炎症敏感参数。CRP 与白蛋白比值(CAR)将这两个参数整合为一个强大的临床参数,其在 2019 年冠状病毒病(COVID-19)背景下的临床和预后相关性尚未得到很好的定义。我们旨在研究 CAR 在 COVID-19 感染背景下的临床和预后意义。
我们回顾性分析了 2020 年 3 月至 2021 年 3 月期间在一家三级医院住院的 2309 例连续 COVID-19 患者的基线数据,这些患者有 CAR 评估的基线数据。研究结果在 2021 年 3 月至 6 月期间住院的 1155 例患者的独立队列中得到验证。
大多数患者(85.8%)入院时患有严重或危重症 COVID-19。中位 CRP、白蛋白和 CAR 水平分别为 91mg/L、32g/L 和 2.92。较高的 CAR 与住院期间呼吸恶化的趋势、需要高流量氧气治疗和机械通气的风险增加、菌血症发生率增加、深静脉血栓形成发生率降低、心肌梗死发生率降低、30 天死亡率增加和出院后死亡率增加相关。我们定义并验证了四个具有不同 30 天生存率的 CAR 预后类别(<1.0、1.0-2.9、3.0-5.9 和≥6.0)。在多变量 Cox 回归模型系列中,我们能够证明 CAR 具有稳健的预后特性,与 COVID-19 严重程度、年龄和合并症无关,并且在发展和验证队列中还与 COVID-19 严重程度、CURB-65 和 VACO 指数独立相关。
CAR 似乎具有改善住院 COVID-19 患者预后的良好潜力。